疏风宣肺汤治疗咳嗽变异性哮喘风邪犯肺证42例疗效观察

Clinical observation of treatment of 42 cases with pathogenic wind attacking lung with cough variant asthma by Shufeng Xuanfei Decoction

目的:观察疏风宣肺汤治疗咳嗽变异性哮喘(CVA)风邪犯肺证的临床疗效。方法:将42例辨证为风邪犯肺证的CVA患者随机分为治疗组及对照组,两组采用相同基础用药,治疗组在基础用药同时加用疏风宣肺汤加减口服,疗程2周,疗程结束后评估临床疗效及安全性。结果:中医证候疗效比较,治疗组总有效率为90.5%,对照组57.1%,有显著性差异(P<0.05);两组咳嗽频率积分、咳嗽程度积分、总积分比较,治疗组较对照组明显降低,差异有统计学意义(P<0.05);两组外周血嗜酸性粒细胞计数比较P=0.610>0.05,差异无统计学意义。两组均无严重不良反应发生。结论:疏风宣肺汤参加减参与治疗咳嗽变异性哮喘(CVA)风邪犯肺证能显著提高临床疗效,安全可靠。

Objective:To observe the clinical efficacy of Shufeng Xuanfei Decoction in the treatment of the syndrome of pathogenicwind attacking lung with cough variant asthma (CVA). Methods:42 patients of the syndrome of pathogenic wind attacking lung with CVAwere randomly divided into the treatment group and the control group. All patients were treated with the conventional therapy, and thetreatment group was additionally treated with Shufeng Xuanfei Decoction. The clinical efficacy and safety was evaluated 2 weeks after thetreatment.Results: Comparison of the efficacy of TCM syndrome showed that the total efficiency in the treatment group was 90.5% andthat in the control group was 57.1%, the difference was statistically significant (P<0.05). The cough frequency integral, cough degreeintegral and total integral were significantly lower in the treatment group than the control group after 2 weeks, the difference wasstatistically significant (P<0.05). Comparison of the peripheral eosinophil count depicted that there was no statistical significance betweenthe treatment group and the control group (P<0.05). No severe adverse effects were found during treatment. Conclusion: Shufeng XuanfeiDecoction in the treatment of patients with the syndrome of pathogenic wind attacking lung with CVA can significantly improve the clinicalefficacy, and it is very safe too.